CEOi - Global CEO Initiative on Alzheimer's Disease

“This is a great time to be in Alzheimer’s research,” says Dr Chi Udeh-Momoh. In this video, Dr. Michelle Mielke and Dr. Momoh share insights into the transformative impact of blood-based tests and their contributions to CEOi’s latest companion publications from the Blood-based Biomarker Workgroup. These new publications provide a clear roadmap for integrating blood tests into clinical practice, marking a major step forward in delivering timely and accurate Alzheimer’s diagnoses. Explore the full recommendations on our website!?https://lnkd.in/eHSQkpmv https://lnkd.in/gi6ynCKD

If you haven't already seen them, now is the perfect time to check out our recent landmark publications in Alzheimer’s & Dementia: “Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease"? "Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease" These publications represent the collective effort of our Blood-Based Biomarker (BBM) Workgroup and signify a crucial step forward in making Alzheimer’s blood tests more accessible and affordable. By establishing clear standards and pathways for clinical implementation, we aim to overcome the current barriers and enhance diagnostic accuracy. Our key findings highlight two clinical implementation pathways for Alzheimer's blood tests: one for immediate use in triaging and another for future use in confirming amyloid pathology. Click here to read the full manuscripts and learn more about the impact of a simplified Alzheimer’s diagnosis pathway: https://lnkd.in/eHSQkpmv Thank you once again to our committed authors and to everyone who supports our mission to advance Alzheimer’s diagnosis, treatment and care. ? Learn more about CEOi here: https://lnkd.in/epC63GZm??

CEOi - Global CEO Initiative on Alzheimer's Disease announced a key milestone in Alzheimer's diagnosis?this morning in two peer-reviewed papers?from their Blood-based Biomarket?Workgroup, published in the Alzheimer's and Dementia journal. Learn more here:?https://lnkd.in/eHSQkpmv

CEOi is excited to announce the publication of two new peer-reviewed, companion publications in Alzheimer’s & Dementia: “Considerations for widespread implementation of blood-based biomarkers of Alzheimer’s disease,” and “Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease.” These pieces mark the second publication by our Blood-Based Biomarker (BBM) Workgroup. These tests have the potential to revolutionize Alzheimer’s diagnosis given their affordability and accessibility advantages compared to current tools; however, clear standards are needed to help providers understand where and how to use them. ? To tackle this challenge, CEOi brought together stakeholders from healthcare, academia, non-profits, government, industry, and patient advocacy to create recommendations for the implementation of Alzheimer’s blood tests.? ? Thank you to our fantastic workstream leads, Dr Chi Udeh-Momoh, Assistant Professor of Epidemiology and Prevention at Wake Forest University School of Medicine and Dr Michelle Mielke, Professor and Chair of Epidemiology and Prevention at Wake Forest University School of Medicine, and all our workstream participants for their leadership and insights. Click here to learn more about our groundbreaking work and read the full versions of both manuscripts: https://lnkd.in/eHSQkpmv Thank you all of our authors for your collaboration and insights! Matthew Anderson, MD, MHA John "Wes" Ashford Andreas Jeromin Pei Jung Lin Allyson Rosen Jamie Tyrone, RN Lawren VandeVrede Deanna Willis Oskar Hansson Ara Khachaturian Suzanne Schindler Joan Weiss Richard Batrla, MD, PhD, MBA Sasha Bozeat John Dwyer Drew Holzapfel Daryl Rhys Jones, PhD Jim Murray Katie Partrick, Ph.D. Emily Scholler, MPH George Vradenburg Dylan Young Joel Braunstein, MD Samantha Burnham Fabricio Ferreira de Oliveira Soeren Mattke Zul Merali Mark Monane, MD, MBA Marwan Sabbagh Eli Shobin Michael Weiner

Fan-girling over the rockstars of the #LausanneXI meeting, our patient and caregiver advocates! Mike Zuendel (and Brooks!) Meryl Comer Initiative to Change the "D-Word" CEOi - Global CEO Initiative on Alzheimer's Disease StartUp Health Davos Alzheimer's Collaborative #Alzheimers #BrainHealth

Did you know? According to Alzheimer's Disease International's World Alzheimer's Report, an astonishing 80% of the public still believes #Alzheimers is a normal part of aging. Yesterday, #LausanneXI panelists Wendy Weidner, Vladimir Hachinski, Khalifah Ismali, Miia Kivipelto, Stephanie Kramer, and Mika Pyykk? called for an urgent shift in how we approach #dementia prevention—emphasizing the need to adopt a life course approach to #brainhealth. Let’s change the narrative and prioritize brain health, viewing our brains as an economic and societal asset, at every stage of life.

From the United States to the Netherlands to Ghana, health systems worldwide face significant challenges in delivering timely, accurate #Alzheimers diagnoses. As emphasized in previous #LausanneXI panels, collaboration is essential. A big thank you to Phyllis Ferrell for leading panelists Edem Adzogenu, Abida Durrani, Jodi Liu, Soeren Mattke, and Eric Reiman in a discussion about the innovative solutions they’re using to tackle these obstacles in their countries, and for underscoring the importance of learning from each other. Together we drive progress and shape a future where every health system has the capabilities and resources to meet the needs of patients and their families.

Our CEO and MoCA creator, Dr. Ziad Nasreddine is proud to be participating in #LausanneXI. It is an honor to connect with Mr. George Vradenburg, Chairman of Davos Alzheimer's Collaborative and Convener of the CEOi - Global CEO Initiative on Alzheimer's Disease This annual event is organized by the CEOi, founded in 2013, is an organization of private-sector leaders who have joined together to provide business leadership in the fight against #Alzheimers. The CEOi believes that, during this era of aging populations, it will take visionary, coordinated, goal-oriented leadership of public and private leaders working together to solve our greatest challenges.

?Update from #LausanneXI.? ADI Deputy CEO Chris Lynch joined an expert panel to hold a dialogue on the subject of 'Data in Action: Building Platforms for Real-World Evidence Generation'. This was a challenging panel that was moderated by Eisai Chief Medical Director Joanne Bell During the discussion, Chris highlighted the need for a timely focus on registries and?real-world evidence, and empowering those living with Alzheimer's disease and dental to have direct access to their own data. Giving individuals the ability to observe their own records in registries could help revolutionise their navigation of risk reduction strategies. Thank you to the entire panel: Carlos Acosta Frank Jessen Robert Perneczky for an insightful discusssion

Live from #LausanneXI: Building stronger platforms for real-world evidence is critical to unlocking the future of #Alzheimers care. Our panelists dove into how this real-world evidence and registries can shape clinical decisions, assess new disease-modifying treatments, and reveal long-term outcomes that matter for both patients and healthcare providers. A big thank you to Joanne Bell, Carlos Acosta, Frank Jenssen, Chris Lynch, and Robert Perneczky for sharing their insights on how we can best build registries and utilize real-world evidence to create meaningful patient outcomes. Alzheimer's Disease International, Eisai US, Biogen